Prelude Therapeutics (PRLD) Cash & Current Investments (2019 - 2026)

Prelude Therapeutics has disclosed Cash & Current Investments across 8 years of filings, most recently posting $144.6 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $144.6 million, up 40.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $144.6 million (up 40.23% YoY), and the FY2025 annual result was $103.2 million, down 25.02% from the prior year.
• Cash & Current Investments came in at $144.6 million for Q1 2026 at Prelude Therapeutics, up from $103.2 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $270.2 million in Q1 2022 to a low of $58.2 million in Q3 2025.
• The 5-year median for Cash & Current Investments is $183.9 million (2024), against an average of $181.2 million.
• Across the five-year window, Cash & Current Investments slumped 63.09% in 2025 and surged 40.23% in 2026, its largest moves.
• Prelude Therapeutics' Cash & Current Investments stood at $205.8 million in 2022, then rose by 15.17% to $237.0 million in 2023, then tumbled by 41.91% to $137.7 million in 2024, then declined by 25.02% to $103.2 million in 2025, then jumped by 40.1% to $144.6 million in 2026.
• The last three Cash & Current Investments figures came in at $144.6 million (Q1 2026), $103.2 million (Q4 2025), and $58.2 million (Q3 2025), per Business Quant data.